Skip to main content
Precision Neuroscience CorpForm D offering

Precision Neuroscience Corp filed a Form D with the SEC, reporting $250.0M sold.

What happened

Precision Neuroscience is a New York-based brain-computer interface company developing a minimally invasive digital connection to the brain for people with paralysis and other neurologic conditions. The company raised approximately $250.0M from 46 investors, a major financing that signals serious momentum and makes it relevant to vendors selling into clinical, medtech, and hospital markets.

Source

Extracted by Autobound

From the Signal API record
Signal
Form D offering

What this signalsNew funding often brings new budget and vendor reviews.

Amount
$250M
Industry group
Other Health Care
Headquarters
New York, NY
Location
New York, NEW YORK
Filed
Sep 28, 2026
Jurisdiction
Delaware

More from Precision Neuroscience Corp

More form D offering signals at other companies

The full record

From the Signal API record

People

  • Michael MagerExecutive Officer, Director · Named in the filing
  • Konstantinos AlatarisExecutive Officer, Director · Named in the filing
  • Craig MermelExecutive Officer, Director · Named in the filing
  • Benjamin RapoportExecutive Officer, Director · Named in the filing
  • Ravi MehtaDirector · Named in the filing
  • Howard MorganDirector · Named in the filing
  • Michael KaswanExecutive Officer · Named in the filing
  • Michael GollerDirector · Named in the filing

Numbers

Amount (USD)
$250M
Investors
46

Details

CIK
0001858288
Form
D
Entity type
Corporation
Primary topic
Biotech Fundraise
Revenue range
Decline to Disclose
Business state
NY
Accession number
0001123292-26-001327
Resolved entity type
Operating company
Has non accredited investors
No
Filer
Precision Neuroscience Corp
Resolved name
Precision Neuroscience

Topics and mentions

Topics

  • Neurotech
  • Medical Devices
  • Healthcare Growth
  • Clinical Partnerships
  • FDA Clearance

Exemptions

  • 06b

Securities

  • Equity

Extraction

Confidence
High
Relevance
86%
Detected
Sep 28, 2026
signal_type
sec-form-d-funding
signal_subtype
newFilingCompany

Use this data

Get every form D offering signal for Precision Neuroscience Corp and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Precision Neuroscience Corp this week?”

  2. Send it to your own tools

    The Signal API returns form D offering signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-form-d-funding record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/fd-0001123292-26-001327 returns this record as JSON. POST /v1/companies/enrich returns every signal for precisionneuro.io.

{
  "signal_id": "fd-0001123292-26-001327",
  "signal_type": "sec-form-d-funding",
  "signal_subtype": "newFilingCompany",
  "detected_at": "2026-09-28T00:00:00+00:00",
  "company": {
    "name": "Precision Neuroscience Corp",
    "domain": "precisionneuro.io"
  },
  "data": {
    "cik": "0001858288",
    "phone": "646-771-5881",
    "detail": "This financing suggests Precision Neuroscience is in a late early-stage to growth-stage phase, with enough capital to push clinical validation, expand hospital partnerships, and advance regulatory/commercial readiness. Based on its website, the company is likely spending on clinical studies, product development, FDA/regulatory work, and scaling its Layer 7 cortical interface platform. Vendors should watch for opportunities in medical device manufacturing, clinical trial services, hospital procurement, data/AI infrastructure, and regulatory/compliance support.",
    "topics": [
      "Neurotech",
      "Medical Devices",
      "Healthcare Growth",
      "Clinical Partnerships",
      "FDA Clearance"
    ],
    "summary": "Precision Neuroscience is a New York-based brain-computer interface company developing a minimally invasive digital connection to the brain for people with paralysis and other neurologic conditions. The company raised approximately $250.0M from 46 investors, a major financing that signals serious momentum and makes it relevant to vendors selling into clinical, medtech, and hospital markets.",
    "website": "https://precisionneuro.io",
    "location": "New York, NEW YORK",
    "file_date": "2026-09-28",
    "form_type": "D",
    "relevance": 0.86,
    "confidence": "high",
    "exemptions": [
      "06b"
    ],
    "filing_url": "https://www.sec.gov/Archives/edgar/data/1858288/000112329226001327/",
    "source_url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001858288&type=D&dateb=&owner=include&count=40",
    "entity_name": "Precision Neuroscience Corp",
    "entity_type": "Corporation",
    "jurisdiction": "DELAWARE",
    "primary_topic": "Biotech Fundraise",
    "revenue_range": "Decline to Disclose",
    "business_state": "NY",
    "industry_group": "Other Health Care",
    "related_persons": [
      {
        "name": "Michael Mager",
        "email": "m***@precisionneuro.io",
        "roles": [
          "Executive Officer",
          "Director"
        ],
        "linkedin_url": "linkedin.com/in/michael-mager-b458437"
      },
      {
        "name": "Konstantinos Alataris",
        "roles": [
          "Executive Officer",
          "Director"
        ]
      },
      {
        "name": "Craig Mermel",
        "email": "c***@precisionneuro.io",
        "roles": [
          "Executive Officer",
          "Director"
        ],
        "linkedin_url": "linkedin.com/in/craig-mermel-62a79b4"
      },
      {
        "name": "Benjamin Rapoport",
        "roles": [
          "Executive Officer",
          "Director"
        ]
      },
      {
        "name": "Ravi Mehta",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Howard Morgan",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Michael Kaswan",
        "roles": [
          "Executive Officer"
        ]
      },
      {
        "name": "Michael Goller",
        "roles": [
          "Director"
        ]
      }
    ],
    "total_investors": 46,
    "accession_number": "0001123292-26-001327",
    "securities_types": [
      "Equity"
    ],
    "business_location": "New York, NY",
    "total_amount_sold": 249999984,
    "resolved_entity_name": "Precision Neuroscience",
    "resolved_entity_type": "operating_company",
    "company_domain_confidence": 10,
    "has_non_accredited_investors": false
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.